Roche launches Vabysmo® (faricimab), the first and only bispecific monoclonal antibody for the eye, to treat two leading causes of vision loss.
by Suman Gupta Vabysmo targets and inhibits two disease pathways that cause neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo’s...